Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

STRATA Skin Sciences (SSKN) Other Non-Current Liabilities (2016 - 2025)

STRATA Skin Sciences' Other Non-Current Liabilities history spans 13 years, with the latest figure at $199000.0 for Q3 2025.

  • For Q3 2025, Other Non-Current Liabilities rose 107.29% year-over-year to $199000.0; the TTM value through Sep 2025 reached $199000.0, up 107.29%, while the annual FY2024 figure was $96000.0, 82.61% down from the prior year.
  • Other Non-Current Liabilities for Q3 2025 was $199000.0 at STRATA Skin Sciences, down from $264000.0 in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $8.6 million in Q1 2022 and bottomed at $24000.0 in Q1 2021.
  • The 5-year median for Other Non-Current Liabilities is $371000.0 (2021), against an average of $2.1 million.
  • The largest annual shift saw Other Non-Current Liabilities surged 35825.0% in 2022 before it crashed 96.46% in 2023.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $428000.0 in 2021, then fell by 26.64% to $314000.0 in 2022, then soared by 75.8% to $552000.0 in 2023, then tumbled by 82.61% to $96000.0 in 2024, then surged by 107.29% to $199000.0 in 2025.
  • Per Business Quant, the three most recent readings for SSKN's Other Non-Current Liabilities are $199000.0 (Q3 2025), $264000.0 (Q2 2025), and $292000.0 (Q1 2025).